1   ***A cis*-element within the *ARF* locus mediates repression of *p16^INK4A* expression**

2   **via long-range chromatin interactions**

3

4   Yang Zhang[a,1], Judith Hyle[a,1], Shaela Wright[a,1], Ying Shao[b], Xujie Zhao[c], Hui Zhang[d] and

5   Chunliang Li[a,*]

6

7   [a]Department of Tumor Cell Biology, St. Jude Children's Research Hospital, 262 Danny

8   Thomas Place, Memphis, TN 38105, USA

9   [b]Department of Computational Biology, St. Jude Children's Research Hospital, 262

10   Danny Thomas Place, Memphis, TN 38105, USA

11   [c]Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, 262

12   Danny Thomas Place, Memphis, TN 38105, USA

13   [d]Department of Hematology and Oncology, Guangzhou Women and Children's Medical

14   Center, Guangzhou Medical University, 9 Jinsui Road, Guangzhou, Guangdong 510623,

15   People's Republic of China.

16

17   [1]These authors contributed equally to this study.

18   [*]To whom correspondence should be addressed. Chunliang Li, PhD. Department of

19   Tumor Cell Biology, St. Jude Children's Research Hospital, 262 Danny Thomas Place,

20   Memphis, TN 38105, USA. Email: chunliang.li@stjude.org; Telephone:1-901-595-6530.

21

22

23

METHODS and MATERIALS

Cell culture

SEM cells (ACC-546, DSMZ) and SK-N-SH cells (HTB11, ATCC) were maintained in RPMI-1640 medium (Hyclone) containing 10% fetal bovine serum (FBS) (HyClone), 2 mM glutamine (Sigma), and 1% penicillin/streptomycin (Thermo Fisher Scientific). All cells were maintained at 37°C in a 5% CO_2 atmosphere and 95% humidity. All cells used in this study were mycoplasma free. Cell identity was confirmed by STR analysis.

Vector construction

All target-specific sgRNAs were predicted using online software (http://crispr.mit.edu/). Oligomers containing 20-bp of the selected target sequence were synthesized by Thermo Fisher Scientific and cloned into the all-in-one vector (1) between BsmBI sites. All oligomer information is listed in *SI Appendix*, Dataset S1. Correct clones were screened and confirmed by Sanger sequencing with the U6-Forward sequencing primer. A two-step cloning protocol was used to generate the long-HA donor vector. Primers were designed to amplify the 800-bp 5′ HA flanking the endogenous sgRNA target. Overhangs of 23-bp, including the target sgRNA and PAM sequences, were included on the 5′ end of the HA sequence. The 3′ HA was generated according to a similar design but included an additional overhang for in-fusion cloning. The HAs were amplified from SEM cell genomic DNA. The *P2A-mCherry* DNA fragment was amplified from pEGFP-C1 (Clontech). SnapGene software (SnapGene) was used to design all primers used for in-fusion cloning (Clontech). The PCR reactions were performed using CloneAmp

47   polymerase (Clontech), and the cycling parameters were as follows for all cloning: 98°C

48   for 2 min, followed by 98°C for 15 s, 55°C for 20 s, and 72°C for 20 s for 40 cycles. First,

49   the amplified 5′ HA for knock-in was cloned into pBluescript-SK by using the TA Cloning

50   Kit (Thermo Fisher Scientific). The DNA was purified from colonies and screened by

51   Sanger sequencing with the primers M13F and M13R. The pBluescript–SK–sgRNA–

52   PAM–5′ HA was then linearized and ligated with *P2A-mCherry* and the 3′ HA–sgRNA–

53   PAM through in-fusion cloning (Clontech). Sanger sequencing was performed to ensure

54   that the knock-in DNA was cloned in-frame with the HAs. The Lenti-dCas9-KRAB-Blast

55   plasmid (#89567) and the LentiGuide-Puro plasmid (#52963) were purchased from

56   Addgene. The primer sequences used for cloning and sequencing are listed in *SI*

57   *Appendix*, Dataset S1.

58

59   **Establishment of a *p16$^{INK4A-P2A-Cherry}$* reporter cell line**

60   SEM were electroporated by using the Nucleofector-2b device (Lonza) with the V-kit and

61   program X-001. For *p16$^{INK4A-P2A-Cherry}$* knock-in delivery, 2.5 µg of the donor plasmid and

62   2.5 µg of the CRISPR/Cas9-p16^{INK4A}-C-terminus-gRNA all-in-one plasmid were used for

63   5 million SEM cells. Twenty-four hours after transfection, cells were sorted for the

64   CRISPR/Cas9-p16^{INK4A}-C-terminus-gRNA vector GFP fluorescent marker to enrich the

65   transfected cell population. After sorted cells recovered in culture for up to 3 weeks, a

66   second sort was performed to select cells for successful knock-in by sorting for cells

67   expressing the knockin mCherry fluorescent marker. Two weeks later, a third sort was

68   repeated for the mCherry fluorescent marker. Single-cell derived colonies were picked up

69   and expanded for further characterization.

70

Characterization of successful knock-in events by PCR and Sanger Sequencing

DNA from single-cell derived colonies was extracted with a PureLink Genomic DNA Mini

Kit (Thermo Fisher Scientific). Combinatorial primer sets designed to recognize the 5′ and

3′ knock-in boundaries were used with the following PCR cycling conditions: 98°C for 2

mins, followed by 40 cycles of 98°C for 15 s, 55°C for 20 s, and 72°C for 20 s. The bands

shown at the expected size in electrophoresis were cut out, purified, and ligated to the

pCR-Blunt II-TOPO vector (Thermo Fisher Scientific) for Sanger sequencing with the

M13F and M13R primers. Heterozygous knockin clones carrying both wildtype allele and

the p16[INK4A-P2A-mCherry] knockin allele were selected for following functional

characterization.

81

CRISPR library construction and screening

A set of 2,029-sgRNA oligos that target on H3K27ac and ATAC-seq positive peaks

defined in the TAD containing *INK4/ARF* in IMR90, HCT116 and SEM cells as well as an

additional 20 non-targeting control sgRNAs with no detectable match to the human

genome were designed for array-based oligonucleotide synthesis (CustomArray). Unique

binding of each sgRNA was verified by sequence blast against the whole human genome.

To construct a sgRNA pooled library targeting on human TFs, seven gRNAs against each

of the 1,639 human TFs were obtained from validated sgRNA libraries published

previously (2-10). For each library, the synthesized oligo pool was amplified by PCR and

cloned into LentiGuide-Puro backbone (#52963) by in-fusion assembly (Clontech). The

p16[INK4A-P2A-mCherry] reporter cell line was overexpressed with lentiviral Cas9 or dCas9-

93 KRAB followed with infection of pooled sgRNA library at low M.O.I (~0.3). Infected cells

94 were selected by blasticidine and puromycin and sorted for mCherry^{High} and mCherry^{Low}

95 populations. The sgRNA sequences were recovered by genomic PCR and Deep

96 Sequencing using MiSeq for single-end 150-bp (Illumina). The primer sequences used

97 for cloning and sequencing are listed in *SI Appendix*, Dataset S1. The sgRNA sequences

98 are described in *SI Appendix*, Datasets S2 and S3. High-titer lentivirus stocks were

99 generated in 293T cells as previously described (1).

100

101 **Data analysis of CRISPR screening**

102 The raw FASTQ data were de-barcoded and mapped to the original reference sgRNA

103 library. The differentially enriched sgRNAs were defined by comparing normalized counts

104 between sorted cells of top 10% and bottom 10% of mCherry-expressing bulk populations.

105 At least three independent replicate screenings were performed with reporter cell lines

106 stably expressing Cas9, dCas9-KRAB and no effector control. Normalized counts for

107 each sgRNA were extracted and used for identifying differentially enriched sgRNA by

108 DESeq2 (11). The combined analysis of seven sgRNAs against each human TF was

109 conducted by MAGeCK algorithm (12). Detailed screening results were included in *SI*

110 *Appendix*, Datasets S2 and S3.

111

112 **Flow cytometry**

113 Suspension cultured SEM were collected by centrifugation at 800X*g*, filtered through a

114 70-µm filter, and analyzed for mCherry on a BD FACS Aria III flow cytometer with a

115 negative control. The 4,6-diamidino-2-phenylindole (DAPI) staining was conducted prior

116 to sort to exclude dead cells.

117

118 **Capture-C**

119 Next-generation Capture-C was performed essentially as described by others (13). In

120 brief, about $1X10^7$ cells were collected per Capture-C reaction. Cells were freshly fixed in

121 1% formaldehyde for 10 mins at room temperature by rotation then quenched by 0.125

122 M glycine followed by resuspension in 5 ml lysis buffer and incubated on ice for 20 mins.

123 The pellets were re-suspended in 1 mL of 1X DpnII buffer and transferred to a 2 mL tube

124 for homogenization followed with centrifugation at 14,000 rpm for 5 mins at 4°C. The

125 supernatant was removed and discarded. The remaining pellets underwent digestion,

126 ligation, and de-crosslinking. After de-crosslinking and DNA precipitation, a small portion

127 of DNA was run on a gel to check for digestion and ligation efficiency. Once the 3C library

128 construction was complete, 5-6 µg of the 3C DNA library was sheared ~200-bp followed

129 with end-repair, adaptor ligation, and PCR enrichment of adaptor ligated DNA. Two

130 rounds of captures were conducted using 1.5-2 µg of DNA, 5 µg COT DNA, and 1 µl xGen

131 Universal Blocking Oligo i7 and 1 µl xGen Universal Blocking Oligo i5 in a 1.5 mL tube.

132 Samples were transferred to thermal cycler at 47 °C for 72 hours for the first capture and

133 16-20 hours for the second capture. The constructed library was sequenced using the

134 Illumina MiSeq System for paired-end 150-bp. The paired-end reads were reconstructed

135 into single reads with FLASH, digested in silico with the DpnII2E.pl script, and aligned to

136 the human genome using Bowtie 1.0.0 (http://bowtie-bio.sourceforge.net/index.shtml).

137 Interaction   frequencies   were   determined   using   CCanalyser2.pl

138   (https://github.com/telenius/captureC/releases). To quantify interaction frequency

139   between bait sequence and target regions, signal value from .bw file was analyzed by

140   "bigWigToBedGraph", and then normalized by probe signal for each experiment (14).

141

142   **CUT&RUN assay**

143   Three million cells were collected for each sample. Cells were pelleted at 600Xg for 3

144   mins at room temperature. Cell pellets were washed twice with 1.5 ml room temperature

145   wash buffer. Cell pellets were resuspended in 1 ml wash buffer at room temperature.

146   While gently mixing, 100 µl concanavalin beads (BioMagAPlus Concanavalin A,

147   Polysciences, 86057-3; prewashed and resuspended in 100 µl binding buffer) were

148   added to the samples, followed with gentle rotation for 10 mins at room temperature.

149   Samples were placed on a magnetic stand and the supernatant was removed. Beads

150   were resuspended in 200 µl AB buffer (Dig-wash buffer with 0.02% digitonin and 0.5 M

151   EDTA) with either ZNF217 antibody (Thermo Fisher Scientific, 720352), Cas9 antibody

152   (Clontech, 632606) or YY1 antibody (Active Motif, 61779). Samples were rotated at 4 °C

153   for 2 hours. Samples were placed on a magnetic stand and supernatant was removed.

154   Beads were gently resuspended in 200 µl Dig-wash buffer with 0.02% digitonin and 2 µl

155   PA-MN (home-made reagent kindly provided by Dr. Steven Henikoff), followed by rotation

156   at 4 °C for 1 hour. Samples were placed on a magnetic stand and supernatant removed.

157   Beads were washed for a total of three times in 1 ml Dig-wash buffer, pipetting gently.

158   Following the final wash, beads were resuspended in 100 µl Dig-wash buffer by gentle

159   mixing and transferred to a new tube. On ice, 2 µl 100 mM $CaCl_2$ was added to the sample

160   with gentle mixing. Samples were incubated on ice for 30 mins. Stop buffer (100 µl) was

161 added to the samples and samples were incubated for 10 mins at 37 °C followed by

162 centrifugation at 4 °C, 12,000 rpm. Samples were placed on a magnetic stand and the

163 supernatant containing the cut and run fragments was collected. To the samples, 2 μl

164 10% SDS and 2.5 μl proteinase K were added and the samples were incubated at 50 °C

165 overnight. DNA was extracted by phenol/chloroform/isopropanol protocol. Library

166 construction was performed using the NEBNext UltraII DNA Library Prep Kit from NEB

167 (E7645S). Indexed samples were run using the Illumina MiSeq V3 600-cycle kit (MS-102-

168 3003). CUT&RUN raw reads were mapped to genome hg19. by bowtie 2.3.4 with default

169 parameter. Then mapping file were converse to .bw file by bamCoverage (15, 16).

170

171 **Immunoblotting**

172 Cells were treated with RIPA buffer, then the lysates were subjected to SDS-PAGE

173 (Thermo Fisher Scientific) and transferred to a PVDF membrane (Bio-Rad) in accordance

174 with the manufacturer's protocols at a constant 100 V for 1 hour. After incubation with 5%

175 nonfat milk in TBS-T (10 mM Tris, pH 8.0, 150 mM NaCl, 0.5% Tween-20) for 1 hour at

176 room temperature, the membrane was incubated with antibodies against GAPDH

177 (Thermo Fisher Scientific, AM4300, diluted 1:5,000), ARF (abcam, ab185620, diluted

178 1:1,000), p16^{INK4A} (abcam, ab189034, diluted 1:1,000), p-RB (Ser807/811, Cell Signaling,

179 8516, diluted 1:1,000), p-RB (Ser780, Cell Signaling, 8180, diluted 1:1,000), RB (Cell

180 Signaling, 9309, diluted 1:1,000) and YY1 antibody (Active Motif, 61779, diluted 1:1,000)

181 at 4°C for 48 hours with gentle shaking. Membranes were washed three times for 30 min

182 and incubated with a 1:2,000 dilution of horseradish peroxidase–conjugated secondary

183 antibodies for 2 hours at room temperature. Blots were washed with TBS-T three times

184   for 30 mins and developed with the ECL system (Amersham Biosciences) in accordance

185   with the manufacturer's instructions.

186

187   **Fluorescence *in situ* hybridization**

188   An 800-bp (homology arms removed) purified DNA (*P2A-mCherry*) sequence was labeled

189   with a red-dUTP (AF594, Molecular Probes) by nick translation, and an *INK4/ARF* fosmid

190   clone (WI2-2622K01/9p21.3) was labeled with a green-dUTP (AF488, Molecular Probes).

191   Both labeled probes were combined with sheared human DNA and independently

192   hybridized to fix the interphase and metaphase nuclei derived from each sample using

193   routine cytogenetic methods in a solution containing 50% formamide, 10% dextran sulfate,

194   and 2XSSC. The cells were then stained with DAPI and analyzed.

195

196   **Quantitative real-time PCR**

197   Total RNA was collected from 1 million cells of SEM or SK-N-SH by using TRIzol (Thermo

198   Fisher Scientific, 15596026). Reverse transcription was performed using a High-Capacity

199   cDNA Reverse Transcriptase Kit (Applied Biosystems, 4374966). Real-time PCR was

200   performed using FAST SYBR Green Master Mix (Applied Biosystems, 4385612) in

201   accordance with the manufacturer's instructions and primers to detect *p16^{INK4A}*, *ARF,*

202   *mCherry*, and *GAPDH*. Relative gene expression was determined by the ΔΔ-CT method

203   (17). qRT-PCR primers were listed in *SI Appendix*, Dataset S1.

204

205   **Statistics**

206   All values are shown as the mean ± SEM. Statistical analyses were performed with

207   GraphPad Prism software, version 6.0. *P*-values were calculated by a two-tailed *t*-test.

208

209   **Abbreviations**

210   CRISPR, clustered regularly interspaced short palindromic repeats; DSB, DNA double-

211   strand break; PAM, protospacer adjacent motif; INDEL, insertion and deletion; bp, base

212   pair; ChIP, chromatin immunoprecipitation; TAD, topologically associated domain; TF,

213   transcription factor; TSS, transcription start site.

214

215
216   **SI Appendix Figure Legends**

217   **Fig. S1 Functional validation of *p16$^{INK4A-P2A-mCherry}$* allele by CRISPR interference**

218   **(CRISPRi)**

219   (A) The *p16$^{mCherry/+}$* reporter cell line was transduced with lentiviral dCas9-KRAB and

220   either NT-sgRNA or p16^{INK4A}-sgRNA-1 that targeted against the *p16^{INK4A}* promoter.

221   Flow cytometry analysis of mCherry fluorescence was demonstrated in

222   comparison to NT-sgRNA targeted cells along with parental SEM cells.

223   (B) qRT-PCR was performed to quantify *p16^{INK4A}* mRNA expression in

224   *p16$^{mCherry/+;dCas9-KRAB}$* cells targeted with either NT-sgRNA or p16^{INK4A}-sgRNA-1

225   (N=4).

226   (C) Immunoblotting was performed on *p16$^{mCherry/+;dCas9-KRAB}$* cells targeted with either

227   p16^{INK4A}-sgRNA-1 or NT-sgRNA by using antibodies against p16^{INK4A}, p-RB1, RB1

228   and GAPDH.

229   (D) Cell number was counted at day 0, 1 and 3 on $p16^{mCherry/+;dCas9\text{-}KRAB}$ cells targeted

230   with either p16^{INK4A}-sgRNA-1 or NT-sgRNA.

231 **Fig. S2 Characterization of non-coding CRISPR sgRNA library by Deep-Sequencing**

232   (A) Maxiprep plasmid DNA containing the CRISPR sgRNA library designed against

233   the entire *INK4/ARF* locus was amplified and sequenced by next-generation

234   sequencing. Counts of each sgRNA were illustrated as $\log_2$ ratio.

235   (B) Deep-sequencing and raw count analysis of the distribution of all sgRNAs 48 hours

236   after library was infected into human IMR90 and HCT116 cells.

237   (C) Pearson's Correlation analysis of the distribution of all sgRNAs amplified from

238   library-infected human IMR90 and HCT116 cells in comparison to maxiprep

239   plasmid DNAs.

240 **Fig. S3 Optimization of the sorting gate of the $p16^{INK4A\text{-}P2A\text{-}mCherry}$ population in non-**

241 **coding CRISPR screening**

242   (A) Flow cytometry sorting was performed in CRISPR sgRNA library–targeted

243         $p16^{mCherry/+;dCas9\text{-}KRAB}$ cells for mCherry^{High} and mCherry^{Low} populations, which were

244   gated at the top and bottom of 5%, 10%, 12%, and 15% sorting gates.

245   (B) The number of sgRNAs that were enriched in the positive-control locus ($p16^{INK4A}$

246   promoter) in each sort was calculated and compared to the total sgRNAs in these

247   regions to determine the enrichment percentage.

248   (C) Pearson's Correlation of the global sgRNA distribution was calculated among the

249   5%, 10%, 12% and 15% sort experiments.

250 **Fig. S4 Enriched sgRNAs in CRISPR/dCas9-KRAB screenings**

251   (A) Volcano plot illustration of CRISPR/Cas9 screening result in combination with

252   arrayed sgRNAs spanning the ATAC-seq and H3K27ac peaks in the *INK4/ARF*

253   locus. The distribution of each sgRNA in the top 10% and bottom 10% of the

254   mCherry sorted population was calculated for a given fold change of

255         $\log_2$(High/Low) (x-axis) and *P*-value (y-axis). Each screening was performed three

256   times to calculate the *P*-value. Under the cut-off of an adjusted *P*-value of ≤0.01

257   and a fold-change of $\log_2^{High/Low}$ ≥1 or ≤−1, purple dots represent sgRNAs

258   designed to target the *p16^{INK4A}* promoter. Red dots represent the non-targeting

259   negative-control sgRNAs. Green dots indicate sgRNAs enriched in the *ARF*

260   promoter. Pink dots indicate sgRNAs enriched in the *p15^{INK4B}* promoter.

261   (B) Volcano plot demonstration of CRISPR/dCas9-KRAB screening result in

262   combination with arrayed sgRNAs spanning the ATAC-seq/H3K27ac peaks in the

263   *INK4/ARF* locus.

264   (C) Volcano plot demonstration of the results of no effector screening in combination

265   with arrayed sgRNAs spanning the ATAC-seq/H3K27ac peaks in the *INK4/ARF*

266   locus.

267   (D) The distribution of sgRNAs in selected viewpoints at *INK4/ARF* locus and a distal

268   non-coding region in three screenings using dCas9-KRAB, Cas9, and no effector

269   control.

270

271 **Fig. S5 Distribution of the full array of sgRNAs from dCas9-KRAB and Cas9**

272 **screening.** All of the 2029 sgRNAs represented in the screening were plotted to genome

273 browser based on enrichment score between mCherry^{High} and mCherry^{Low}.

274

Fig. S6 Distal repressive elements residing 3' and adjacent to the *ARF* promoter contribute to the repression of *p16^{INK4A}*

    (A) The physical location of all four sgRNAs targeting the *p16^{INK4A}* repressive element adjacent to the *ARF* promoter (ARF-sgRNA-1, 2, 3 and 4).

    (B) Validation of four randomly selected sgRNAs targeting the *p16^{INK4A}* promoter (p16^{INK4A}-sgRNA-1, 2, 3 and 4) and two sgRNAs targeting the *ARF* promoter (ARF-sgRNA-1 and 2) outside the 42-bp core sequence. Lentiviral sgRNA infection into *p16^{mCherry/+;dCas9-KRAB}* cells was performed, followed by flow cytometry analysis of the mCherry density. The *p*-values were calculated by a two-tailed *t*-test.

Fig. S7 Acute depletion of CTCF in SEM cells by auxin-inducible degron (AID) system did not affect expression of *p16^{INK4A}*

    (A) ChIP-seq tracks of CTCF, SMC3 and YY1 on the *INK4/ARF* locus based on ENCODE data from GM12878 and SK-N-SH cells.

    (B) Schematic illustration of working mechanism of auxin-inducible degron system.

    (C) Schematic diagram of donor vector design for miniAID-mClover3 knock-in to C-terminus of human *CTCF* before the stop codon. HA: homology arm. Single-guide RNA (sgRNA) and PAM sequences were added to each end of the HA.

    (D) A Bi-allelic knock-in clone and a mono-allelic knock-in clone were used to detect protein degradation after IAA treatment for 24 hours. The CTCF-miniAID-mClover3 fusion protein was 35 KD larger than endogenous CTCF. GAPDH was included as loading control.

296   (E) CUT&RUN of CTCF was conducted in SEM^{CTCF-AID} knockin cells (clones 35 and

297   42) treated with or without IAA for 48 hours. A representative set of consistent data

298   from one clone (clone 42) was shown. Tracks were shown at the viewpoint of

299   *INK4/ARF* locus.

300   (F) qRT-PCR analysis of *p16^{INK4A}* was conducted in three bi-allelic knock-in clones in

301   response to CTCF depletion.

302   (G) Immunoblotting was performed using antibody against p16^{INK4A} in four individual

303   bi-allelic knock-in clones in response to CTCF depletion.

304

REFERENCES

306   1.   Vo BT, *et al.* (2017) Inactivation of Ezh2 Upregulates Gfi1 and Drives Aggressive Myc-
307   Driven Group 3 Medulloblastoma. *Cell Rep* 18(12):2907-2917.
308   2.   Wang T, *et al.* (2015) Identification and characterization of essential genes in the human
309   genome. *Science* 350(6264):1096-1101.
310   3.   Doench JG, *et al.* (2016) Optimized sgRNA design to maximize activity and minimize off-
311   target effects of CRISPR-Cas9. *Nat Biotechnol* 34(2):184-191.
312   4.   Sanjana NE, Shalem O, & Zhang F (2014) Improved vectors and genome-wide libraries
313   for CRISPR screening. *Nat Methods* 11(8):783-784.
314   5.   Ma H, *et al.* (2015) A CRISPR-Based Screen Identifies Genes Essential for West-Nile-
315   Virus-Induced Cell Death. *Cell Rep* 12(4):673-683.
316   6.   Tzelepis K, *et al.* (2016) A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and
317   Therapeutic Targets in Acute Myeloid Leukemia. *Cell Rep* 17(4):1193-1205.
318   7.   Hart T, *et al.* (2015) High-Resolution CRISPR Screens Reveal Fitness Genes and
319   Genotype-Specific Cancer Liabilities. *Cell* 163(6):1515-1526.
320   8.   Hart T, *et al.* (2017) Evaluation and Design of Genome-Wide CRISPR/SpCas9 Knockout
321   Screens. *G3 (Bethesda)* 7(8):2719-2727.
322   9.   Smith JR, *et al.* (2008) Robust, persistent transgene expression in human embryonic
323   stem cells is achieved with AAVS1-targeted integration. *Stem Cells* 26(2):496-504.
324   10.   Park RJ, *et al.* (2017) A genome-wide CRISPR screen identifies a restricted set of HIV host
325   dependency factors. *Nat Genet* 49(2):193-203.
326   11.   Love MI, Huber W, & Anders S (2014) Moderated estimation of fold change and
327   dispersion for RNA-seq data with DESeq2. *Genome Biol* 15(12):550.
328   12.   Li W, *et al.* (2014) MAGeCK enables robust identification of essential genes from
329   genome-scale CRISPR/Cas9 knockout screens. *Genome Biol* 15(12):554.

330 13.   Davies JO*, et al.* (2016) Multiplexed analysis of chromosome conformation at vastly
331   improved sensitivity. *Nat Methods* 13(1):74-80.
332 14.   Kent WJ, Zweig AS, Barber G, Hinrichs AS, & Karolchik D (2010) BigWig and BigBed:
333   enabling browsing of large distributed datasets. *Bioinformatics* 26(17):2204-2207.
334 15.   Langmead B & Salzberg SL (2012) Fast gapped-read alignment with Bowtie 2. *Nat*
335   *Methods* 9(4):357-359.
336 16.   Ramirez F, Dundar F, Diehl S, Gruning BA, & Manke T (2014) deepTools: a flexible
337   platform for exploring deep-sequencing data. *Nucleic Acids Res* 42(Web Server
338   issue):W187-191.
339 17.   Schmittgen TD & Livak KJ (2008) Analyzing real-time PCR data by the comparative C(T)
340   method. *Nat Protoc* 3(6):1101-1108.
341

Figure S1

A

Negative Control
NT-sgRNA
$p16^{INK4A}$-sgRNA-1

B

$p16^{INK4A}$

**** $p<0.0001$

dCas9-KRAB +NT sgRNA

dCas9-KRAB +p16^{INK4A}-sgRNA-1

C

dCas9-KRAB

p16^{INK4A}-sgRNA-1

NT sgRNA

p16^{INK4A}
p-RB1(Ser807/811)
p-RB1(Ser780)
RB1
GAPDH

D

**** $p<0.0001$

* $p=0.02$

dCas9-KRAB+

NT sgRNA
p16^{INK4A}-sgRNA-1
NT sgRNA
p16^{INK4A}-sgRNA-1
NT sgRNA
p16^{INK4A}-sgRNA-1

Day 0   Day 1   Day 3

Figure S2

A

B

C

Figure S3

A

Negative control

Representative gating of sort

mCherry^Low

mCherry^High

Live cells / mCherry

B

Enriched positive control sgRNAs %

Sorting gate %

C

	Log_2FC 15%	Log_2FC 12%	Log_2FC 10%	Log_2FC 5%
Log_2FC 15%	1			
Log_2FC 12%	0.91	1		
Log_2FC 10%	0.9	0.94	1	
Log_2FC 5%	0.74	0.77	0.78	1

-1   -0.6   -0.2   0.2   0.6   1

Figure S4

A

Cas9

$p16^{INK4A}$ sgRNAs — Log$_{10}$ adjust P-value vs Log$_2$FC (mCherry$^{High/Low}$)

ARF sgRNAs — Log$_{10}$ adjust P-value vs Log$_2$FC (mCherry$^{High/Low}$)

$p15^{INK4B}$ sgRNAs — Log$_{10}$ adjust P-value vs Log$_2$FC (mCherry$^{High/Low}$)

B

dCas9-KRAB

Log$_{10}$ adjust P-value vs Log$_2$FC (mCherry$^{High/Low}$)

C

No effector

Log$_{10}$ adjust P-value vs Log$_2$FC (mCherry$^{High/Low}$)

D

chr9:21,972,948-21,977,072   chr9:21,989,913-22,001,129   chr9:22,068,445-22,127,102

dCas9-KRAB screening
mCherry$^{High/Low}$
Log$_2$FC

Cas9-screening
mCherry$^{High/Low}$
Log$_2$FC

No effector
mCherry$^{High/Low}$
Log$_2$FC

$p16^{INK4A}$

ARF
$CDKN2B$-AS

Non-coding region

Figure S5

Figure S6

A

chr9:21,993,061-21,996,707

dCas9-KRAB screening
$Log_2FC^{mCherry(High/Low)}$

Cas9-screening
$Log_2FC^{mCherry(High/Low)}$

ARF-sgRNA-1

ARF-sgRNA-2

ARF-sgRNA-3

ARF-sgRNA-4

Annotation

ARF *CDKN2B-AS1*

B

Q-PCR of $p16^{INK4A}$
***$p < 0.001$

*$p = 0.03$
**$p = 0.01$

Relative fold

NT sgRNA
ARF-sgRNA-1
ARF-sgRNA-2
$p16^{INK4A}$-sgRNA-1
$p16^{INK4A}$-sgRNA-2
$p16^{INK4A}$-sgRNA-3
$p16^{INK4A}$-sgRNA-4

Figure S7

A

chr9:21,754,542-22,486,494

CTCF
- GM12878 — 0-20
- SK-N-SH — 0-20

SMC3
- GM12878 — 0-50
- SK-N-SH — 0-50

YY1
- GM12878 — 0-20
- SK-N-SH — 0-20

Annotation

MTAP   *p16^INK4A*   *DMRTA1*

ARF

p15^INK4B

B

Auxin-inducible degron system

Target protein — miniAID — mClover3

Auxin

Target protein — miniAID — mClover3

Auxin

Rbx1 E2   ubiquitin

Cul1   Ostir1

Skp1

Proteasome Mediated Degradation

C

CTCF C-terminus knock-in

stop codon

Endo-gRNA-PAM

HA-5'800bp   miniAID-mClover3   HA-3'800bp

Endo-gRNA-PAM   Endo-gRNA-PAM

D

CTCF^AID/AID   CTCF^AID/+

IAA: +   -   +   -

KI>
WT>   WB: CTCF

WB: GAPDH

E

CTCF CUT&RUN   chr9:21,916,011-22,046,230

CTCF^AID-IAA   0-80

CTCF^AID+IAA   0-80

p16^INK4A   *ARF* *p15^INK4B*

F

Relative expression *p16^INK4A*

NS

NS

IAA: 0 hr   24 hrs   48 hrs

G

CTCF^AID/AID clone 1   CTCF^AID/AID clone 2   CTCF^AID/AID clone 3   CTCF^AID/AID clone 4

IAA: +   -   +   -   +   -   +   -

WB: p16^INK4A

WB: GAPDH